Table 3.
Copper IUD | Ulipristal Acetate | Levonorgestrel | Yuzpe | |||||
---|---|---|---|---|---|---|---|---|
aOR | 95% CI | aOR | 95% CI | aOR | 95% CI | aOR | 95% CI | |
Reproductive Health Specialists | ||||||||
% women of reproductive age in practice | ||||||||
All or most | 2.93 | 1.00–8.58 | 3.67* | 1.28–10.56 | 5.09 | 0.47–55.59 | 3.27* | 1.25–8.52 |
About half | 1.22 | 0.35–4.21 | 4.58* | 1.36–15.48 | 1.98 | 0.14–27.82 | 2.09 | 0.67–6.59 |
Small proportion | ref | ref | ref | ref | ||||
Provider type | ||||||||
CNM, PA, NP | 0.47* | 0.24–0.90 | 0.66 | 0.39–1.12 | 3.22 | 0.31–33.00 | 0.35*** | 0.20–0.62 |
Resident or Fellow | 1.67 | 0.40–7.06 | 0.78 | 0.39–1.54 | 0.16 | 0.00–5.79 | 0.69 | 0.30–1.56 |
Staff Physician | ref | ref | ref | ref | ||||
Non-Reproductive Health Specialists | ||||||||
Specialty | ||||||||
Family Practice | 1.88*** | 1.32–2.67 | 1.41 | 0.94–2.13 | 3.96** | 1.51–10.38 | 1.84** | 1.28–2.66 |
Pediatrics/Adolescent | 0.75 | 0.53–1.05 | 1.45 | 0.98–2.14 | 2.16* | 1.05–4.44 | 1.40 | 0.99–1.97 |
Emergency Medicine | 0.42*** | 0.27–0.64 | 0.74 | 0.44–1.24 | 1.73 | 0.81–3.67 | 0.65 | 0.42–1.03 |
Internal Medicine | ref | ref | ref | ref | ||||
% women of reproductive age in practice | ||||||||
All or most | 3.41*** | 2.00–5.81 | 5.96*** | 3.49–10.19 | 4.49 | 0.59–34.00 | 2.92*** | 1.71–4.96 |
About half | 1.77*** | 1.31–2.39 | 1.94*** | 1.37–2.75 | 1.29 | 0.71–2.35 | 1.50* | 1.10–2.05 |
Small proportion | ref | ref | ref | ref | ||||
Provider type | ||||||||
CNM, PA, NP | 0.72 | 0.48–1.08 | 0.68 | 0.43–1.08 | 0.38** | 0.19–0.73 | 0.33*** | 0.20–0.53 |
Resident or Fellow | 1.44 | 0.93–2.23 | 1.33 | 0.78–2.29 | 1.91 | 0.56–6.50 | 1.57 | 0.99–2.50 |
Staff Physician | ref | ref | ref | ref |
Results shown from multivariate logistic regression; models include the following covariates: years in practice, practicing in an academic setting, and gender of provider
Significant at p <0.05;
Significant at p <0.01;
Significant at p <0.001